Aegis Awarded 3rd Patent for Fast Acting Migraine Nasal Spray Treatment

barbara.lempert

’ Intravail® formulation of sumatriptan achieves therapeutic drug levels in approximately 2 to 3 minutes

SAN DIEGO, CA Aug 13, 2013 — Aegis Therapeutics LLC announced today that it has been a third for formulations of triptans, a widely used class of drugs including sumatriptan, zolmitriptan, naratriptan, rizatriptan, eletriptan, almotriptan and frovatriptan, that are highly effective in treating headaches. New Zealand Patent No. 5937828 is the first international Aegis patent covering the triptans to issue providing patent coverage through December 2029.  Numerous additional international patent applications are in process worldwide. Human clinical trials have shown that the Intravail® formulation of sumatriptan achieves therapeutic drug levels at approximately 2 to 3 minutes, 20 to 30 times faster that the currently marketed non-injectable sumatriptan products.  For comparison, the most widely used triptan formulations, namely sumatriptan or tablet formulations, both reach maximum blood levels of drug in about 60 to 120 minutes thus delaying onset of relief.  The total triptan market exceeds $ 3 billion annually, with sumatriptan comprising approximately $ 2 billion of the total.

The enabling Aegis Intravail formulation technology is broadly applicable to a wide range of small molecule and biotherapeutic drugs to increase noninvasive bioavailability by the oral, nasal, buccal, and sublingual routes and to speed attainment of therapeutic drug levels in cases where speed is important to the patient, for example in the of pain, nausea, emesis, convulsive disorders, spasticity, and the like.

Aegis technology is commercialized by our licensees who conduct the actual product development and marketing activities. Aegis’ licensees include five of the top 10 largest pharmaceutical companies and two of the top 10 largest generics companies, along with many public and private biotech…Read more

Pharmalive – The Pulse of the Pharmaceutical Industry

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS